Navigation Links
New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
Date:5/5/2008

ontained herein should be construed as a profit forecast.

(*) The MADRS scale measures the severity of a number of depressive symptoms including mood and sadness, tension, sleep, appetite, energy, concentration, suicidal ideation, and restlessness. The MADRS score decreases as depressive symptoms improve.(12)

(+) The CGI-S score refers to the global impression of the patient and requires clinical experience with the syndrome under assessment. The CGI improvement scale can be completed only following or during treatment. The concept of improvement refers to the clinical distance between the individual's current condition and that prior to the start of treatment.(12)

(++) The HAM-A rating scale consists of 14 items and measures the severity of symptoms such as anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, restlessness, and other physical symptoms.(12)

(S) HAM-A response is defined as greater than or equal to 50% decrease in HAM-A total score from baseline(4)

(**) HAM-A remission is defined as HAM-A total score less than or equal to 7.4

References:

(1) Weisler R, Joyce M, McGill L, et al. Extended release Quetiapine fumarate (quetiapine XR) monotherapy for major depressive disorder (MDD): a double-blind, placebo-controlled study [poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8, 2008, Washington, D.C., USA.

(2) Datto C, Lam RW, Lepola U, et al. Double-blind study of extended release quetiapine fumarate (quetiapine XR) monotherapy for maintenance treatment of major depressive disorder (MDD) [poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8,2008, Washington, D.C., USA.

(3) El-Khalili N, Joyce M, Atkinson S, et al. Adjunctive extended-release quetiapine fumarate (quetiapine XR) in patients with major depressive disorder and inadequate antidepressant response [poster]. Presented at:
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
2. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
3. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
4. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
5. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
6. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
7. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
10. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
11. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., PITTSBURGH, Nov. 24 ,, WHAT:...in coma for 23 years following an auto accident, w...time and was the subject of a Good Morning America...segment to illustrate how people with Locked-in Sy...on. ,, WHEN: Good Morning America -- Tuesday,...
(Date:11/24/2009)..., MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ ...the world,s leading provider of diagnostic testing...cheduled to speak at the 21st Annual Piper Jaffray...entation is scheduled for Wednesday, December 2, 2...nference, the company will reaffirm its 2009 guida...
(Date:11/24/2009)... SAN DIEGO, Nov. 24 Anad...d today that it will present at the 21st Annual Pi...mber 1, 2009 at 9:00 a.m. EST (6:00 a.m. PST). Th...Hotel. Steve Worland, Ph.D., President and Chief ...iew of Anadys and its clinical development program...
Breaking Medicine Technology:DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Bausch 26amp 3B Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 5214 1Bausch 26amp 3B Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 5214 2IncentOne Introduces Next Generation of Healthy Choice Award 28TM 29 Incentive Solution to Drive Consumer and Provider Engagement 5209 1IncentOne Introduces Next Generation of Healthy Choice Award 28TM 29 Incentive Solution to Drive Consumer and Provider Engagement 5209 2Prostate cancer gives a new outlook on life 58853 1Prostate cancer gives a new outlook on life 58853 2
... Published in May Issue of Journal of Sexual Medic...ny (NYSE: LLY ) today announced results from a d... that tadalafil 5 mg dose taken once daily was gen...for men with erectile dysfunction (ED) and reporte... for men and their female partners. The 12-week st...
...vorable results for secondary endpoints support ou...a Pharmaceuticals, Inc., a privately held biopharm...gs, announced today that FRANCIS (Fewer Recurrent ...r Inflammation Suppression), a clinical trial desi... when administered to patients within 96 hours of ...
Other Medicine Technology:Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples 2Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples 3Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples 4Study Reported Tadalafil Taken Once Daily Improved Erectile Function in Men with ED and Sexual Quality of Life in Couples 5Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 2Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 3Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome 4
(Date:11/26/2009)...tions announces a highly effective and unconventio...g to make an economic recovery. , ... the type of challenge that could send ailing holi...David Benton, business growth expert and author of... The Rfactor Intensive . “Fear is one of ...
(Date:11/25/2009)...ire-USNewswire/ -- When most people hear the acron...ractor can also give patients the help they need. ...h is where your jaw (mandible) contacts/connects w...mmon symptoms associated with TMJ dysfunction are ... But many other symptoms can be caused from TMJ d...
(Date:11/25/2009)... Onyx Pharmaceuticals, ...pany will host two investor events in December: ,...:00 a.m. CT/10:00 a.m. ET ,, Principal invest...g carfilzomib in relapsed and/or refractory multip...ty of Hematology (ASH) Annual Meeting and Expositi...
(Date:11/25/2009)...- Sentinelle Medical Inc., a leading manufacturer ...tware launches a suite of new leading edge clinica...ftware platform at this year,s Radiological Societ...o, Nov. 30 - Dec. 5, 2009 (Booth 5800, Hall A). Th...ages generated by Sentinelle,s specialized MRI ima...
(Date:11/25/2009).... 25 An article by Jane... Drug Evaluation and Research, titled "A Difficult...DA," appears in the Nov. 26, 2009 issue of The New.../www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ...ts to strike a balance between access to pain medi...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 4
...ceived that smoking accelerates the risk of heart ...tte has the inherent capacity for the development ...ppears to have a startling - and almost immediate ...urs of developing symptoms had bigger blood clots ...
...sults from a study on a vaccine made from the immu...t to be a promising. Dr. Johannes Vieweg, associat...of immunology at Duke University Medical Center in...ells (WBC) that activate the immune system by impe...
... approved the first pocket-sized EKG machine, so s...ments in ambulances, the emergency room - even a p...he first hand-held computer-based medical device, ...of the heart's electrical signals, used to diagnos...
...nting compound in broccoli, first isolated a decad... broader spectrum of diseases.A new study shows th... themselves for two or three days against highly r...s compound is a covert operative that works indire...
...dy suggests that the much famed tanning salons, wh...ease the chances of a number of more common skin c...urnal of the National Cancer Institute claims to h...esearchers from the Dartmouth Medical School in th...
...r a couple of drinks is a common problem for heavy...which was a mystery until now.It may support the p...the University of Ohio College of Medicine and the...ssels do not strengthen so effectively after drink...
Other Medicine News:
Omni-Flex Knee Retractor System
...lin, lipocalin-2) is a new early marker for acute ...a >90% positive predictive value. NGAL is dramatic... hours after renal injury. This makes NGAL an idea...,Quantitative determination of NGAL in human urine...
... used for monitoring the measurements of total hem...strumentation. It provides an alternative for thos...ologic range for tHb, O2Hb, and COHb. QC 253 is av...r performance at varying points within the clinica...
QC 233 CO-Oximeter Control
Medicine Products: